Literature DB >> 16538528

Angiopoietin 2 expression in invasive ductal carcinoma of the breast: its relationship to the VEGF expression and microvessel density.

Shinichi Tsutsui1, Hiroshi Inoue, Kazuhiro Yasuda, Kosuke Suzuki, Hideya Takeuchi, Takashi Nishizaki, Hidefumi Higashi, Shoichi Era, Masaki Mori.   

Abstract

Angiopoietin (Ang) is a ligand for the endothelium-specific tyrosine kinase receptor Tie-2, while a shift in the Ang-1:Ang-2 expression ratio in favor of Ang-2 was found to be associated with tumor angiogenesis. In the present study, we analyzed the immunohistochemical expression of Ang-2 in a series of 198 breast cancers, in which VEGF expression and microvessel density (MVD) were previously determined. Ang-2 expression was negative in 24 (12%), positive in 50 (25%) and strongly positive in 124 (63%) of 198 cases. A significant correlation was found between Ang-2 and VEGF expressions (p=0.0004) and between Ang-2 expression and MVD (p=0.0006), while a high MVD was found in 10 (77%) of 13 tumors with a strongly positive VEGF and positive Ang-2 expression and in 40 (71%) of 56 tumors with a strongly positive VEGF and strongly positive Ang-2 expression. Although there was no difference in the disease free survival (DFS) stratified according to Ang-2 expression alone, the 69 patients with a strongly positive VEGF and a strongly positive or positive Ang-2 expression had a significantly (p=0.0316) worse DFS than those with other combinations of VEGF and Ang-2 expressions. A multivariate analysis indicated lymph node metastasis and MVD to be independently significant prognostic factors for DFS, while the combination of VEGF and Ang-2 expressions was not a significant factor for DFS. In conclusion, the Ang-2 expression was found to be closely correlated with VEGF expression and MVD in breast cancer, while a high MVD was frequently found in tumors with a high expression of both VEGF and Ang-2. The survival analysis demonstrated a high MVD, which was induced by a high expression of both VEGF and Ang-2, to therefore have a strong prognostic significance in breast cancer.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16538528     DOI: 10.1007/s10549-005-9157-9

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  22 in total

1.  Expression of hypoxia-inducible factor-1alpha and the protein products of its target genes in diabetic fibrovascular epiretinal membranes.

Authors:  Ahmed M Abu El-Asrar; Luc Missotten; Karel Geboes
Journal:  Br J Ophthalmol       Date:  2007-01-17       Impact factor: 4.638

2.  Inhibition of endothelial/smooth muscle cell contact loss by the investigational angiopoietin-2 antibody MEDI3617.

Authors:  Nikolett Molnar; Dietmar W Siemann
Journal:  Microvasc Res       Date:  2012-02-23       Impact factor: 3.514

3.  The Selective Tie2 Inhibitor Rebastinib Blocks Recruitment and Function of Tie2Hi Macrophages in Breast Cancer and Pancreatic Neuroendocrine Tumors.

Authors:  Allison S Harney; George S Karagiannis; Jeanine Pignatelli; Bryan D Smith; Ece Kadioglu; Scott C Wise; Molly M Hood; Michael D Kaufman; Cynthia B Leary; Wei-Ping Lu; Gada Al-Ani; Xiaoming Chen; David Entenberg; Maja H Oktay; Yarong Wang; Lawrence Chun; Michele De Palma; Joan G Jones; Daniel L Flynn; John S Condeelis
Journal:  Mol Cancer Ther       Date:  2017-08-24       Impact factor: 6.261

4.  Angiogenetic axis angiopoietins/Tie2 and VEGF in familial breast cancer.

Authors:  K Danza; B Pilato; R Lacalamita; T Addati; F Giotta; A Bruno; A Paradiso; S Tommasi
Journal:  Eur J Hum Genet       Date:  2012-12-12       Impact factor: 4.246

Review 5.  Targeting the ANGPT-TIE2 pathway in malignancy.

Authors:  Hanhua Huang; Abhijit Bhat; Gary Woodnutt; Rodney Lappe
Journal:  Nat Rev Cancer       Date:  2010-08       Impact factor: 60.716

6.  Host-derived angiopoietin-2 affects early stages of tumor development and vessel maturation but is dispensable for later stages of tumor growth.

Authors:  Patrick Nasarre; Markus Thomas; Karoline Kruse; Iris Helfrich; Vivien Wolter; Carleen Deppermann; Dirk Schadendorf; Gavin Thurston; Ulrike Fiedler; Hellmut G Augustin
Journal:  Cancer Res       Date:  2009-02-10       Impact factor: 12.701

7.  A phase II trial of brivanib in recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study.

Authors:  Matthew A Powell; Michael W Sill; Paul J Goodfellow; Doris M Benbrook; Heather A Lankes; Kimberly K Leslie; Yvette Jeske; Robert S Mannel; Monique A Spillman; Paula S Lee; James S Hoffman; D Scott McMeekin; Pamela M Pollock
Journal:  Gynecol Oncol       Date:  2014-07-11       Impact factor: 5.482

8.  Autocrine release of angiopoietin-2 mediates cerebrovascular disintegration in Moyamoya disease.

Authors:  Kinga G Blecharz; Dietmar Frey; Tobias Schenkel; Vincent Prinz; Gloria Bedini; Susanne M Krug; Marcus Czabanka; Josephin Wagner; Michael Fromm; Anna Bersano; Peter Vajkoczy
Journal:  J Cereb Blood Flow Metab       Date:  2016-01-01       Impact factor: 6.200

9.  Can the delayed phase of quantitative contrast-enhanced mammography improve the diagnostic performance on breast masses?

Authors:  Weimin Xu; Bowen Zheng; Weiguo Chen; Chanjuan Wen; Hui Zeng; Zilong He; Genggeng Qin; Yingjia Li
Journal:  Quant Imaging Med Surg       Date:  2021-08

10.  Pharmacological inhibition of DNA methylation induces proinvasive and prometastatic genes in vitro and in vivo.

Authors:  Bushra Ateeq; Alexander Unterberger; Moshe Szyf; Shafaat A Rabbani
Journal:  Neoplasia       Date:  2008-03       Impact factor: 5.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.